Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Soliton Inc (SOLY)

Soliton Inc (SOLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 167,407
  • Shares Outstanding, K 16,944
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,750 K
  • 60-Month Beta 0.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 21.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.37 +18.68%
on 05/04/20
10.70 -7.20%
on 05/28/20
+0.58 (+6.20%)
since 04/29/20
3-Month
6.64 +49.55%
on 03/20/20
12.50 -20.56%
on 03/04/20
-0.60 (-5.70%)
since 02/28/20
52-Week
6.64 +49.55%
on 03/20/20
24.75 -59.88%
on 05/30/19
-10.35 (-51.04%)
since 05/29/19

Most Recent Stories

More News
Soliton Announces Pivotal Cellulite Clinical Trial Results to be Presented at AAD Virtual Meeting June 12-14

, /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that the results from its pivotal...

SOLY : 9.93 (+0.51%)
Soliton Reports First Quarter 2020 Results

, /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today reported financial results for the first...

SOLY : 9.93 (+0.51%)
Soliton Announces First Quarter 2020 Financial Results and Business Update on Thursday, May 14, 2020

, May 7, 2020 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, announced today that it will report...

SOLY : 9.93 (+0.51%)
Soliton Granted New Key Patent for FDA Cleared RAP Technology

Soliton, Inc. (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced the U.S. Patent and Trademark Office granted the Company's...

SOLY : 9.93 (+0.51%)
Soliton Announces New Launch Plan of Next Generation Acoustic Shockwave Product Due to COVID-19

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today provided an update on its business strategy and financial position...

SOLY : 9.93 (+0.51%)
Soliton to Present Pivotal Cellulite Clinical Trial Results at Virtual AAD 2020 Annual Meeting

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...

SOLY : 9.93 (+0.51%)
Lead Investigator Evaluates Next-Step for Soliton Pivotal Cellulite Clinical Data

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...

SOLY : 9.93 (+0.51%)
Soliton Receives FDA Clearance of Special 510(k)

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...

SOLY : 9.93 (+0.51%)
Soliton signs Agreement with Global Manufacturer Sanmina

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...

SANM : 26.61 (-1.26%)
SOLY : 9.93 (+0.51%)
Soliton to Present Pivotal Cellulite Clinical Trial Results at AAD on March 21, 2020

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson...

SOLY : 9.93 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SOLY with:

Business Summary

Soliton Inc. is a medical device company. Its commercial product uses rapid pulses of designed acoustic shockwaves to dramatically accelerate the removal of unwanted tattoos. Soliton Inc. is based in Houston, Texas.

See More

Key Turning Points

2nd Resistance Point 10.24
1st Resistance Point 10.08
Last Price 9.93
1st Support Level 9.70
2nd Support Level 9.48

See More

52-Week High 24.75
Fibonacci 61.8% 17.83
Fibonacci 50% 15.69
Fibonacci 38.2% 13.56
Last Price 9.93
52-Week Low 6.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar